Navigation Links
Protein Sciences Announces Signing of a Forbearance Agreement With Emergent BioSolutions

MERIDEN, Conn., April 30 /PRNewswire/ -- Protein Sciences Corporation ("PSC"), a privately owned company based in Meriden, CT, announced today that it had signed an agreement with Emergent BioSolutions, Inc. ("EBS"), a publicly traded company (NYSE: EBS), headquartered in Rockville, MD, establishing the terms for the repayment of the loan that Emergent made to PSC in 2008, terminating the 2008 Asset Purchase Agreement between the parties and resolving the outstanding litigation.

Daniel D. Adams, President and CEO of Protein Sciences said, "We are pleased to have an agreement in place with Emergent covering repayment of the loan and resolution of the litigation. The agreement provides for a reasonable amount of time to secure the funds needed to repay Emergent and the ability to retain a level of funds necessary to sustain our operations prior to repayment. We believe that with this agreement in place we will be able to secure funding from investors, strategic partners or through major contracts."

About PSC. PSC is a biopharmaceutical company, whose mission it is to save lives and improve health by effectively responding to our changing world with innovative vaccines and biopharmaceuticals. PSC uses recombinant DNA technology to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. The active ingredients in all of the firm's products are recombinant proteins that are manufactured, using its patented protein expression technology, based upon baculovirus and insect cell technology.

In response to the current health emergency declared by the Department of Health and Human Services, PSC is developing a vaccine for the potential pandemic swine flu (PanBlok(R)) and expects to be manufacturing the vaccine within six weeks and to be able to produce 20,000 to 30,000 doses per week.

The Company's lead product is FluBlok(R), a seasonal recombinant trivalent influenza vaccine, consisting of influenza hemagglutin (HA) proteins. FluBlok is manufactured without the use of eggs, is highly purified and therefore does not require the use of thimerosal or antibiotics and is low in endotoxins. PSC filed a Biologics License Application for FluBlok with the FDA in April 2008 that was accepted for filing in June 2008 and received "Fast Track" designation in July, 2008. PSC anticipates that FluBlok will be approved in time for the 2009/2010 influenza season.

Our web site is (

SOURCE Protein Sciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
2. Cell Biosciences Launches Next-Generation Protein Characterization System
3. Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
4. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
5. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
6. Researchers at the University of Georgia Discover Protein is Crucial to Reproduction of Parasites Involved in Disease
7. Max Muscle Introduces First-Ever Probiotics Protein Bar
8. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
9. Cell Biosciences Introduces Kits for Oncoprotein Analysis
10. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
11. Max Planck Institute of Biochemistry Uses MathWorks Tools in Its Quest to Cure Cancer : Institute Accelerates Reconstruction of Key Protein Complexes Using MATLAB and Parallel Computing Toolbox
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):